A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants with Spinal Cord Injury

Biological/cell based

General health

Online since 9 June 2025, updated today

About this trial

This trial is enrolling 10 participants with spinal cord injury to test the safety of a cell therapy (LCTOPC1) delivered via a novel surgical device. LCTOPC1 is an experimental treatment using oligodendrocyte progenitor cells derived from human embryonic stem cells. If included, participants will receive a single injection of 10 million LCTOPC1 cells into the injured area of the spinal cord. Final assessment of safety will be performed after 3 months.

Included participants

Gender

All

Age

18 - 65 years

Injury level

C4 - T10

Severity (AIS)?

AIS-A

AIS-B

Time since injury

21 days - 5 years

Injury type

Traumatic

Healthy volunteers

C4-T10

What’s involved

Type

Biological/cell based

Details

- Participants will receive a single injection of 10 million LCTOPC1 cells into the injured area of the spinal cord. - LCTOPC1 is an experimental treatment made from human embryonic stem cells. - Final assessment of safety will be performed after 3 months.

Potential benefits

Main benefits

General health

Additional benefits

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results